BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors ...
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...
TipRanks on MSN
Tenaya Therapeutics Advances Genetic Therapy for Heart Disease: A Closer Look at the TN-201 Study
Tenaya Therapeutics, Inc. (($TNYA)) announced an update on their ongoing clinical study. Tenaya Therapeutics, Inc. is conducting a pivotal ...
The intervention being tested is RP-A501, a genetic therapy involving a recombinant adeno-associated virus serotype 9 (AAV9) vector carrying the human LAMP2B transgene. It is administered as a single ...
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback